Notice2021-14129
Government-Owned Inventions; Availability for Licensing
Primary source
Metadata and text below are from the Federal Register, a public-domain U.S. government work. Always verify the official published version before relying on it for any legal matter.
Published
July 1, 2021
Issuing agencies
Health and Human Services DepartmentNational Institutes of Health
Abstract
The invention listed below is owned by an agency of the U.S. Government and is available for licensing to achieve expeditious commercialization of results of federally-funded research and development. Foreign patent applications are filed on selected inventions to extend market coverage for companies and may also be available for licensing.
Full Text
<html>
<head>
<title>Federal Register, Volume 86 Issue 124 (Thursday, July 1, 2021)</title>
</head>
<body><pre>
[Federal Register Volume 86, Number 124 (Thursday, July 1, 2021)]
[Notices]
[Pages 35100-35101]
From the Federal Register Online via the Government Publishing Office [<a href="http://www.gpo.gov">www.gpo.gov</a>]
[FR Doc No: 2021-14129]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions; Availability for Licensing
AGENCY: National Institutes of Health, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The invention listed below is owned by an agency of the U.S.
Government and is available for licensing to achieve expeditious
commercialization of results of federally-funded research and
development. Foreign patent applications are filed on selected
inventions to extend market coverage for companies and may also be
available for licensing.
FOR FURTHER INFORMATION CONTACT: David Yang at 240-695-6406 or
<a href="/cdn-cgi/l/email-protection#661f0708011655260b070f0a48080f0e48010910"><span class="__cf_email__" data-cfemail="ccb5ada2abbcff8ca1ada5a0e2a2a5a4e2aba3ba">[email protected]</span></a>. Licensing information may be obtained by
communicating with the Technology Transfer and Intellectual Property
Office, National Institute of Allergy and Infectious Diseases, 5601
Fishers Lane, Rockville, MD 20852; tel. 301-496-2644. A signed
Confidential Disclosure Agreement will be required to receive copies of
unpublished information related to the invention.
SUPPLEMENTARY INFORMATION: Technology description follows:
Pre-Biotic Formulation of Topical Chemicals for Use on Human Skin
Description of Technology: Atopic dermatitis (AD) is a common,
recurrent, chronic inflammatory skin disease that is a cause of
considerable economic and social burden. It is one of the most
prevalent skin disorders, affecting ~25% of children in developed and
developing countries and is expected to continue to escalate. This
increased rate of incidence has changed the focus of research on AD
toward epidemiology, prevention, and treatment.
[[Page 35101]]
Scientists at NIAID have developed novel topical formulations that
promote the growth of health-associated strains of commensal bacteria
and inhibit disease-associated bacteria, thereby enhancing skin health.
This technology is available for licensing for commercial
development in accordance with 35 U.S.C. 209 and 37 CFR part 404, as
well as for further development and evaluation under a research
collaboration.
Potential Commercial Applications:
<bullet> Over-the-counter formulations--this invention could be readily
incorporated into popular body lotions or other skincare products to
make ``enhanced''/``microbiome-friendly'' versions that promote the
growth of health associated bacterial
Competitive Advantages:
<bullet> Benign safety profile with multiple mechanisms of action
<bullet> Proven enhancement of beneficial microbiota
<bullet> Can be readily incorporated into existing products
Development Stage:
<bullet> Pre-clinical
Inventors: Carlos Castillo and Ian Myles, MD, MPH, both of NIAID.
Publications: Castillo, Carlos, et al. ``Assessing the effects of
common topical exposures on skin bacteria associated with atopic
dermatitis'', Skin Health and Disease, 2021.05.07.
Intellectual Property: HHS Reference No. E-100-2021-0; US
provisional application No. 63/175,368 filed on April 15, 2021.
Licensing Contact: To license this technology, please contact David
Yang at 240-695-6406 or <a href="/cdn-cgi/l/email-protection#96eff7f8f1e6a5d6fbf7fffab8f8fffeb8f1f9e0"><span class="__cf_email__" data-cfemail="e099818e8790d3a08d81898cce8e8988ce878f96">[email protected]</span></a> and reference E-100-2021-0.
Collaborative Research Opportunity: The National Institute of
Allergy and Infectious Diseases is seeking statements of capability or
interest from parties interested in collaborative research to further
develop, evaluate or commercialize this technology. For collaboration
opportunities, please contact David Yang at 240-695-6406 or
<a href="/cdn-cgi/l/email-protection#027b636c657231426f636b6e2c6c6b6a2c656d74"><span class="__cf_email__" data-cfemail="acd5cdc2cbdc9fecc1cdc5c082c2c5c482cbc3da">[email protected]</span></a>.
Dated: June 24, 2021.
Surekha Vathyam,
Deputy Director, Technology Transfer and Intellectual Property Office,
National Institute of Allergy and Infectious Diseases.
[FR Doc. 2021-14129 Filed 6-30-21; 8:45 am]
BILLING CODE 4140-01-P
</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>Indexed from Federal Register on July 1, 2021.
This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.